Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Aripiprazole Treatment of Prodromal Patients|
- Total Score of the Scale Of Prodromal Symptoms [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]This is a 19-item scale with items scores 0-6. Treatment response is defined as all 5 Scale of Prodromal Syndromes positive symtpom items being rate below the prodromal range (< or equal to 2).
|Study Start Date:||February 2004|
|Study Completion Date:||February 2007|
|Primary Completion Date:||February 2007 (Final data collection date for primary outcome measure)|
This is an 8 week trial with extension for responders out to one year. All patients receive active medication; there is no placebo. Patients must meet criteria for the schizophrenia prodrome according to the Structured Interview for Prodromal Syndromes. Patients receive counseling as well. All counseling and medication are free of charge.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00237874
|United States, Connecticut|
|Institute of Living|
|Hartford, Connecticut, United States, 06106|
|Yale School of Medicine|
|New Haven, Connecticut, United States, 06512|
|Principal Investigator:||Scott W Woods, MD||Yale University|